AACR 2021
Let's collaborate Boehringer Ingelheim

AACR 2021

AACR 2021 - American Association for Cancer Research Congress 2021

The annual AACR meeting covers the latest discoveries across the spectrum of cancer research – from population science and prevention; to cancer biology, translational and clinical studies; to survivorship and advocacy – and highlights the work of the best minds in research and medicine from institutions all over the world. This year, the congress will take place in a virtual format. To find out more about the program, click here.

 

Boehringer Ingelheim is dedicated to collaborating with the oncology community on a shared journey to deliver innovative treatments for patients with lung cancer and other tumor types. At the congress, we will be presenting cutting-edge scientific discoveries in cancer cell-directed agents and immuno-oncology therapies. More information is provided below.

12 publications
Week 1: Saturday 10 April – Thursday 15 April, 2021; Week 2: Monday 17 May – Friday 21 May, 2021
Virtual format

AACR Presentations

AACR Presentations

Download
AACR 2021 Hipp Slides

A novel B7-H6/CD3 bispecific IgG-like T cell engaging antibody for CRC

Download
AACR 2021 Kraut Slides

Expanding the reach of precision oncology by drugging all KRAS mutants

Publications

Explore our latest clinical and pre-clinical data during the scientific program at AACR 2021.  

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumor Type
  • All tumor types
Publications
UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations
Author(s): Miura et al.
Poster Presentation
Tumor Type(s): NSCLC
Presentation Number: LB138
Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors
Author(s): Harrington et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: CT217
Enhancing cytotoxic chemotherapy effects by nintedanib* in gastric cancer preclinical models
Author(s): Awasthi et al.
Poster Presentation
Tumor Type(s): gastric cancer
Presentation Number: 1043
In vitro and in vivo characterization of BI 1823911 – a novel KRAS G12C selective small molecule inhibitor
Author(s): Savarese et al.
Poster Presentation
Tumor Type(s): NSCLC and CRC
Presentation Number: 1271
BI 905711 selectively induces apoptosis and anti-tumor response in TRAILR2/CDH17-expressing pancreatic cancer models
Author(s): Han et al.
Poster Presentation
Tumor Type(s): pancreatic cancer
Presentation Number: 985
Preclinical evaluation of VEGF/Ang2 bispecific nanobody BI 836880 in patient-derived xenograft models of nasopharyngeal carcinoma
Author(s): Wong et al.
Poster Presentation
Tumor Type(s): head and neck cancer
Presentation Number: 948
SMAC mimetics and BET inhibitors – a promising combination for solid cancer treatment?
Author(s): Traexler et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: 1951
Novel EGFR WT sparing, HER2 selective inhibitors for the treatment of HER2 exon 20 insertion driven tumors address a clear unmet medical need
Author(s): Neumüller et al.
Poster Presentation
Tumor Type(s): NSCLC
Presentation Number: 1472
Trial in process: Phase 1 studies of BI 1701963, a SOS1::KRAS inhibitor, in combination with MEK inhibitors, irreversible KRAS G12C inhibitors or irinotecan
Author(s): Hofmann et al.
Poster Presentation
Tumor Type(s): solid tumors
Presentation Number: CT210
A novel B7-H6/CD3 bispecific IgG-like T cell engaging antibody for the treatment of colorectal cancer
Author(s): Hipp et al.
e-Presentation
Tumor Type(s): CRC
Abstract Number: 56
Blocking SIRPα on myeloid cells synergizes with radiation therapy in mouse breast cancer models
Presenter(s): Lhuillier et al.
e-Presentation
Tumor Type(s): breast cancer
Abstract Number: LB168
There are no publications which meet your criteria on this date
Monday, May 17 – Friday, May 21, 2021
Expanding the reach of precision oncology by drugging all KRAS mutants
Author(s): Kraut et al.

Meet-the-expert session

e-Presentation
Tumor Type(s): solid tumors
Abstract Number: ME49
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

 

Related Information

Our pipeline

Find out more about our clinical development pipeline

NSCLC in focus

An overview of recent advances in the treatment of advanced/metastatic non-small cell lung cancer

THERAPEUTIC STRATEGIES: TARGETING APOPTOSIS IN CANCER

View our downloadable resource on targeting apoptosis in cancer
Back to top

Pipeline compounds shown here are under pre-clinical and/or clinical investigation, and have not been approved. Their safety and efficacy have not been established.

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

© 2021 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: September 2021